Conferences - Results from #840

Viewing 841-860 of 11869 articles

EAU 2024: State-of-the-Art Lecture: Advancements in Cutting-Edge SBRT Therapy for Oligometastatic Kidney Cancer

EAU 2024: A Prospective, Comparative, Within-Patient Controlled Multicenter Phase III Study Comparing Blue Light Cystoscopy Versus White Light Cystoscopy for the Detection of Bladder Cancer Using Modern HD 4K Equipment

EAU 2024: Risk Adapted Screening for Prostate Cancer in Europe: PSA + Risk Calculators + MRI (The EAU Screening Algorithm)

EAU 2024: Non-Thermal Atmospheric Plasma Ablation for Intermediate Risk Non-Muscle Invasive Bladder Cancer: A First in Human Trial

EAU 2024: Is There a Role for BCG in Very High-Risk Non-Muscle Invasive Bladder Carcinoma? Multicenter Analysis of Oncological Outcomes and Risk Dynamics

EAU 2024: Subsequent Therapies After Intravesical BCG in Patients with Bladder Cancer: Analysis of Real-World Treatment Patterns

EAU 2024: PSMA-PET Guided Intensification of Salvage Radiotherapy after Radical Prostatectomy: a Phase 2 Randomized Controlled Trial

EAU 2024: Intravesical Administration of Durvalumab to Patients with High Risk Non-Muscle Invasive Bladder Cancer Who Experience BCG Failure. Final Results from a Phase II Study by the Hellenic GU Cancer Group

EAU 2024: The International Bladder Cancer Group Intermediate-Risk Non-Muscle Invasive Bladder Cancer (IBCG IR-NMIBC) Scoring System Predicts the Need for Intervention for Patients on Active Surveillance

EAU 2024: Three-Year Oncological Outcomes of the Randomized Phase II Trial ARNEO: Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-Risk Prostate Cancer

EAU 2024: PSICHE Trial: PSMA Guided Approach for Biochemical Relapse After Prostatectomy- a Prospective Trial

EAU 2024: Two-Year Quality of Life (QoL) Outcomes of the Randomized Phase II Trial ARNEO: Neoadjuvant Degarelix with or without Apalutamide Prior to Radical Prostatectomy for High-Risk Prostate Cancer

EAU 2024: Does Audit, Feedback and Education Improve Quality Indicator Achievement and Reduce Early Recurrence Rates in TURBT Surgery for NMIBC? Results from the RESECT Cluster Randomised Trial

EAU 2024: Identifying the Optimal Definition of PSA Response After Metastasis Directed Therapy in Men with Oligo-Recurrent Prostate Cancer Detected at PSMA PET

EAU 2024: First Results of the Phase Ib-II BladderGATE Clinical Trial: Intravenous Atezolizumab + Intravesical Bacillus Calmette-Guérin (BCG) Upfront Combination in BCG-Naïve High Risk Non-Muscle Invasive Bladder Cancer Patients

EAU 2024: Outpatient Laser Coagulation of Low-Grade Intermediate Risk Bladder Tumor Compared with TURBT, 12 Months and Long-Term Follow-up of a Noninferiority RCT

EAU 2024: A Phase II Clinical Trial of Neoadjuvant Sasanlimab and Stereotactic Body Radiation Therapy as an in Situ Vaccine for Cisplatin Ineligible Muscle Invasive Bladder Cancer

EAU 2024: Challenging the Paradigm of BCG Unresponsive Bladder Cancer: Does Additional BCG Have an Effect?

EAU 2024: Avoiding Overtreatment using PSA Doubling Time Kinetics: Long-Term Management of BCR Following RARP

EAU 2024: PIONEER: Development of a Predictive Model for Death Amongst Patients with mHSPC Treated with One of the Approved Treatment Plans Based on Characteristics Present at Admission Using Big Data

38
39
40
41
42
43
44
45
46
47